Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high morbidity and mortality worldwide. In affected people, insulin is unable to ...

In 2021, a research team discovered the insulin-inhibitory receptor 'Inceptor' and its role as a suppressor of the insulin signaling pathway. Now, the researchers have unlocked another, even more ...

Research targeting the insulin-inhibitory receptor, or inceptor, unveils promising avenues for beta cell protection, offering hope for causal diabetes therapy. These findings, led by Helmholtz Munich ...

Developing resistance to insulin is a key step on the road to diabetes, making insulin resistance a target for treating metabolic dysfunction. Insulin orchestrates blood glucose levels by signaling ...

The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study. Blocking ...

A team led by Novo Nordisk’s Rita Slaaby developed the glucose-responsive insulin, which is called NNC2215. The insulin in NNC2215 makes links to two moieties: a glucose-binding macrocycle and a ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...

A new study uncovers how endothelial cells contribute to insulin resistance in obesity-associated diabetes, highlighting adrenomedullin as a potential therapeutic target. Study: Endothelial insulin ...